Patents Assigned to Universite de Montpellier
  • Publication number: 20180222888
    Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Application
    Filed: April 5, 2018
    Publication date: August 9, 2018
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre ROUX, Florence MAHUTEAU, Romain NAJMAN, Gilles GADEA, Jamal TAZI, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC
  • Patent number: 10030009
    Abstract: A compound of general formula (I) in which R1, R2, R3 and R5, identical or different, each represent a hydrogen atom or a hydroxyl group, optionally protected by a protecting group. R4 represents a hydrogen atom or an —OR7 group, in which R7 represents a hydrogen atom, a protecting group or a gallate group. R6 represents a hydroxyl group, optionally protected by a protecting group. R?1, R?2, R?3 and R?4, identical or different, each represent a hydrogen atom or a substituent not comprising a mesomeric electron withdrawing group conjugated with the furan ring. A substituent from R?1, R?2, R?3 and R?4 representing the covalent bond with the pyran ring or one of the salts of same. A method for obtaining such a compound includes a step of depolymerization of condensed tannins in the presence of an acid by means of a nucleophile derived from furan.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 24, 2018
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CENTRE INTERNATIONAL D'ETUDES SUPERIEURES EN SCIENCES AGRONOMIQUES, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Roumeas, Hélène Fulcrand, Chahinez Aouf, Eric Dubreucq
  • Publication number: 20180200408
    Abstract: The present invention relates to hydrogels prepared using silylated organic molecules (such as silylated biomolecules), a method for obtaining same, and uses thereof.
    Type: Application
    Filed: July 7, 2016
    Publication date: July 19, 2018
    Applicants: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean Martinez, Ahmad Mehdi, Gilles Subra, Said Jebors, Cécile Echalier
  • Patent number: 10017498
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R? is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n? is 1 or 2.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 10, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Publication number: 20180186934
    Abstract: The present invention relates to a cross-linkable composition comprising: i) a fluorinated ?,?-bis(propargyl) oligomer of formula (I): in which m is 1 to 100, e.g. 1 to 93, n is 2 to 150, e.g. 1 to 128, p is 0 to 2 preferably 0 or 1.75, and, n, m and p are selected such that the fluorinated ?,?-bis(propargyl) oligomer of formula (I) has a number average molar mass Mn of 400 to 25000; ii) a cross-linking agent comprising at least three azide-N3 groups; and iii) optionally, a fluorinated oligomer comprising two terminal azide-N3 or fluorinated ?,?-bis(azide) oligomer groups. The invention also relates to a material comprising the click chemistry reaction product of the cross-linkable composition of the invention, to a method for preparing said material and to the uses thereof.
    Type: Application
    Filed: July 1, 2016
    Publication date: July 5, 2018
    Applicants: SAFRAN ELECTRICAL & POWER, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Mathieu CHARLAS, Donatien Henri Edouard MARTINEAU, Gerald Pierre Maurice LOPEZ, Jean-Pierre HABAS, Bruno AMEDURI
  • Patent number: 10011620
    Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: July 3, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
    Inventors: Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
  • Patent number: 10001491
    Abstract: The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 19, 2018
    Assignees: Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: David Azria, Jerome Lacombe, Jerome Solassol, Alain Mange
  • Patent number: 9995579
    Abstract: A tiltmeter to measure a variation in inclination of a structure from a given starting position. The tiltmeter has two pots, each pot contains an identical volume and identical height of an identical liquid. A communication device connects the two pots and allows the liquid to flow between the two pots by the principle of communicating vessels. Two optical measuring devices are provided, one optical measuring device per pot. Each optical measuring device measures a variation in height of the level of liquid in the associated pot. The optical measuring devices are fiber optic devices coupled to a common light source.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: June 12, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC, UNIVERSITE DE MONTPELLIER
    Inventor: Frederick Boudin
  • Patent number: 9988727
    Abstract: An electrode is provided that is suitable for use with the electrolysis of water in a liquid electrolyte medium, the electrode formulated by the following formulation method: a) dissolving, in a volatile solvent or a mixture of volatile solvents, at least one ion-conducting polymer binder that allows, in the solid state, the diffusion of the gases formed during electrolysis; b) adding, to the solution obtained in step a), at least one electrocatalytic material in the form of divided powder, in order to obtain a mixture; and c) depositing the mixture obtained in step b) on a metallic or metallic-type conductive support or collector, said support or said collector being openwork and chemically stable in an aqueous medium, steps a) and b) being able to be implemented simultaneously, successively or to be reversed.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 5, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, BULANE
    Inventors: Alexandra Patru, Frederic Favier, Nicolas Jerez
  • Patent number: 9987327
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: June 5, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSITANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, UNIVERSITE D'ANGERS
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • Patent number: 9982266
    Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 29, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER
    Inventor: Magali Taulan-Cadars
  • Publication number: 20180142321
    Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.
    Type: Application
    Filed: May 3, 2016
    Publication date: May 24, 2018
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Fanny MARY, Guilhem ARRACHART, Stephane PELLET-ROSTAING, Antoine LEYDIER, Veronique DUBOIS
  • Patent number: 9969715
    Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: May 15, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
  • Patent number: 9932594
    Abstract: The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct administration into the peripheral nervous system (PNS) of a patient (e.g., formulated for intrathecal administration).
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 3, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier
    Inventors: Patrick Carroll, Alexandre Pattyn, Stephanie Venteo
  • Patent number: 9932410
    Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 3, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, Universite Paris- Sud, Institut Regional du Cancer du Montpellier, Ecole Normale Superieure de Cachan
    Inventors: Marie-Alix Poul, Mariane Le Gall, Ronan Crepin
  • Patent number: 9931416
    Abstract: The present invention relates to anti-claudin 1 antibodies for use in the treatment of colorectal cancer. In particular, the present invention relates to a method of treating a colorectal cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an anti-claudin 1 (CLDN1) antibody.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: April 3, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: Marguerite Del Rio, Nadia Vezzio-Vie
  • Patent number: 9908869
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R? is a hydrogen atom or a (C1-C4)alkyl group; n? is 1 or 2; n is 1, 2, or 3; R independently represents a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —NR1R2 group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a (C1-C3)fluoroalkoxy, and a (C1-C4)alkoxy group; R? is a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a (C1-C4)alkoxy group, and a CN group; R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group; with the proviso that when R and R? are not simultaneously a hydrogen atom: when n is 1, R is not a methyl group in an ortho or para position with respect to N, when R? is a hydrogen atom, R is not a bromine atom or a chlorine atom, and when R is a hydrogen atom, R? is not a methyl or ethyl group, a —COOH group, a —COOC2H5 group, or a bromine atom that
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 6, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • Publication number: 20180052166
    Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.
    Type: Application
    Filed: July 10, 2015
    Publication date: February 22, 2018
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Martin Villalba Gonzalez, Ewelina Krzywinska
  • Patent number: 9890112
    Abstract: The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: February 13, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Romain Najman, Florence Mahuteau, Pierre Roux
  • Patent number: 9850364
    Abstract: Process for the preparation of a vinylidene chloride polymer composite comprising a solid particulate encapsulated in the vinylidene chloride polymer. The process comprises providing a dispersion of a solid particulate material in a liquid phase, said dispersion comprising a RAFT/MADIX agent; providing vinylidene chloride and optionally one or more ethylenically unsaturated monomer copolymerizable therewith to said dispersion; and polymerizing vinylidene chloride and said optionally present one or more ethylenically unsaturated monomer under the control of said RAFT/MADIX agent to form polymer at the surface of said solid particulate material.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 26, 2017
    Assignees: Solvay SA, Centre National De La Recherche Scientifique, Ecole Nationale Superieure De Chimie De Montpellier, Universite De Montpellier 2
    Inventors: Jérôme Vinas, Pierre-Emmanuel Dufils, Jérôme Garnier, Patrick Lacroix-Desmazes, Alex Van Herk, Jérôme Warnant, Yves Vanderveken